Jefferies downgraded Sciclone Pharmaceuticals, Inc. (Nasdaq: SCLN) from Buy to Hold; $6.00 price target. The firm based their recommendation on ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE